RESUMEN

With the prolongation of the mean lifespan, the number of elderly individuals undergoing liver resection for colorectal cancer liver metastasis (CRLM) following chemotherapy has increased. However, the effect of age on the development of chemotherapy-associated liver injury (CALI) in CRLM remains unclear. The aim of the present study was to elucidate the effect of age on the development of CALI in CRLM. A total of 64 patients undergoing liver resection for CRLM following oxaliplatin-based chemotherapy (OBC) were investigated. The patients were divided into three groups (group A: <65 years, group B: 65-74 years and group C: >75 years) according to age at surgery, and the development rate of CALI was compared between the groups. The patients underwent pathological assessments to determine the degree of histopathological injury of the non-cancerous liver parenchyma. Group A included 37 cases, group B 17 cases and group C 10 cases. There were no significant differences among the groups regarding the number of OBC cycles and duration of OBC cessation. Sinusoidal injury was observed in 27.0, 29.4 and 30.0% of the cases in groups A, B and C, respectively; the differences were not statistically significant (P=0.479). Steatohepatitis was observed in 35.1, 35.3 and 40.0% of the cases in groups A, B and C, respectively; the differences were not statistically significant (P=0.958). There was no significant correlation between age and sinusoidal pathological score (r=-0.102, P=0.423) or non-alcoholic fatty liver disease activity score (r≤0.001, P=0.997). Therefore, the development of CALI following OBC treatment in CRLM was not found to differ by age.

RESUMEN

A 72-year-old woman was diagnosed with gallbladder cancer and underwent extended cholecystectomy and extrahepatic bile duct resection. The pathological findings were CGnBdGb, circ, nodular infiltrating type, 20×10 mm, tub2, pT3b, int, INF c, ly1, v1, ne3, pN0, pDM0, pHM0, pEM0, pPV0, pA0, R0, Stage III A. Because the main localization was in the cystic duct, we diagnosed this as cystic duct cancer. Seven months after surgery, follow-up computed tomography scan revealed a metastatic region in segment 7 of the liver. She underwent chemotherapy with gemcitabine(GEM). After 3 courses of GEM, the metastatic lesion became obscure. After 8 courses, the metastatic lesion disappeared, and the patient showed complete response. We discontinued chemotherapy after 21courses of GEM, and the patient is alive with no signs of recurrence 4 years and 4 months after surgery.

Asunto(s)

RESUMEN

Esophageal neuroendocrine carcinoma is relatively rare and the prognosis is poor owing to its aggressive malignancy. We experienced a case of neuroendocrine carcinoma of the esophagus treated with neoadjuvant chemotherapy of 5-fluorouracil plus cisplatin. A 71-year-old man was diagnosed with esophageal carcinoma(clinical T3N1M0, Stage III ). He received neoadjuvant chemotherapy comprising 5-fluorouracil plus cisplatin, followed by subtotal esophagectomy with dissection of 3 regional lymph nodes. Immunohistochemical findings were synaptophysin-positive, CD56-positive, Ki-67(labeling index) B90%. The final diagnosis was neuroendocrine carcinoma, categorized as CT-pT1a-MM, pN0, Stage 0. The pathological response to neoadjuvant chemotherapy was Grade 2. The patient is alive 8 months after esophagectomy without metastasis.

Asunto(s)

Asunto(s)

RESUMEN

BACKGROUND: Blood transfusion is linked to a negative outcome for malignant tumors. The aim of this study was to evaluate aggressive surgical resection for hilar cholangiocarcinoma (HCCA) and assess the impact of perioperative blood transfusion on long-term survival. METHODS: Sixty-six consecutive major hepatectomies with en bloc resection of the caudate lobe and extrahepatic bile duct for HCCA were performed using macroscopically curative resection at our institute from 2002 to 2012. Clinicopathologic factors for recurrence and survival were retrospectively assessed. RESULTS: Overall survival rates at 1, 3, and 5 years were 86.7, 47.3, and 35.7 %, respectively. In univariate analysis, perioperative blood transfusion and a histological positive margin were two of several variables found to be significant prognostic factors for recurrence or survival (P<0.05). In multivariate analysis, only perioperative blood transfusion was independently associated with recurrence (hazard ratio (HR)=2.839 (95 % confidence interval (CI), 1.370-5.884), P=0.005), while perioperative blood transfusion (HR=3.383 (95 % CI, 1.499-7.637), P=0.003) and R1 resection (HR=3.125 (95 % CI, 1.025-9.530), P=0.045) were independent risk factors for poor survival. CONCLUSIONS: Perioperative blood transfusion is a strong predictor of poor survival after radical hepatectomy for HCCA. We suggest that circumvention of perioperative blood transfusion can play an important role in long-term survival for patients with HCCA.

Asunto(s)

RESUMEN

Surgical resection is the only curative treatment for biliary tract cancer; however, it is only feasible if the cancer is detected at an early stage. Since early diagnoses are difficult, most patients are diagnosed when the cancer is at an unresectable, advanced stage. Current treatments for unresectable cases include radiotherapy and chemotherapy, although it remains difficult to achieve long-term survival. We herein present our experience with a case of unresectable biliary tract cancer that exhibited an effective response to chemotherapy with gemcitabine plus cisplatin (GEM+CDDP). The patient was a 76- year-old man with biliary tract cancer( T2N1M0, cStage III). Multiple liver metastases were detected during laparotomy. We judged the tumor to be unresectable and placed a biliary tract metallic stent. After surgery, we initiated chemotherapy with GEM+CDDP. No liver metastases were visualized on computed tomography (CT) after 5 courses of chemotherapy. We considered surgical resection; however, the patient chose to continue chemotherapy. Currently, the patient is alive and well without any recurrence of liver metastasis, 26 months after surgery.

Asunto(s)

RESUMEN

A 48-year-old woman was admitted to our hospital for the treatment of a liver tumor (diameter, 10 cm), which was detected by abdominal contrast-enhanced computed tomography. The tumor occupied mainly the left medial segment and caudate lobe, invaded the left and right hepatic arteries, and obstructed the left portal vein. The tumor was diagnosed as an unresectable intrahepatic cholangiocarcinoma, and chemotherapy (a combination of gemcitabine and S-1) was initiated. Because the tumor continued to grow despite the chemotherapy, we performed transarterial chemoembolization(TACE)as a second-line treatment, which successfully reduced tumor size to 7 cm. Thereafter, surgical resection was performed. Histopathological examination indicated the presence of intrahepatic cholangiocarcinoma, which formed the main component, combined with hepatocellular carcinoma. This tumor was diagnosed as a combined hepatocellular and cholangiocarcinoma. Although adjuvant chemotherapy was not administered because of prolonged pancytopenia, currently, at 5 years after the operation, the patient is alive and has not experienced any recurrence.

Asunto(s)

RESUMEN

The patient was a 36-year-old female who had undergone Auchincloss operation for left breast cancer at another hospital when 29 years old. Three years ago she was transferred from another hospital to our department complaining of dyspnea. Under the diagnosis of cardiac tamponade, we treated her with pericardial drainage and systemic chemotherapy (intravenous dosage of trastuzumab and vinorelbine: VNR), and then pericardial effusion disappeared. Further medical treatment was continued on an outpatient basis. One year later, cardiac tamponade developed again. We performed echo-guided pericardiocentesis and removed 600 mL of bloody effusion. The cytology of the effusion showed class V. Pericardial effusion recurred, so we instilled OK-432 and mitomycin C (MMC) twice. After that the cytology diagnosis became negative, and the heart shadow in chest X-P reduced. The pericardial effusion has never occurred until now. We also gave her systemic chemotherapy (intravenous dosage of trastuzumab)and endocrine therapy (peroral administration of medroxyprogesterone acetate). She made a remarkable recovery with these treatments and could go back to work.

Asunto(s)